Search

Your search keyword '"Bizien L"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Bizien L" Remove constraint Author: "Bizien L"
47 results on '"Bizien L"'

Search Results

1. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

2. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

3. Le déficit en interféron de type I n’altère pas la réponse lymphocytaire B mémoire contre le SARS-CoV-2 après vaccination par ARNm

4. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

5. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19

6. Autoantibodies neutralizing type I IFNs are present in similar to 4\% of uninfected individuals over 70 years old and account for similar to 20\% of COVID-19 deaths

7. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

8. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

9. Autoantibodies against type I IFNs in patients with life-threatening COVID-19

10. Autoantibodies against type I IFNs in patients with life-threatening COVID-19

11. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

12. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19

13. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

14. The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies

15. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

16. Similar Kinetics of Pulmonary SARS-CoV-2 Load in Intensive Care Unit Patients with COVID-19 Pneumonia with or Without Autoantibodies Neutralizing Type I Interferons.

17. Incontinentia pigmenti underlies thymic dysplasia, autoantibodies to type I IFNs, and viral diseases.

18. A sensitive assay for measuring whole-blood responses to type I IFNs.

19. SARS-CoV-2 brainstem encephalitis in human inherited DBR1 deficiency.

20. Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease.

21. Microglial TNFα controls daily changes in synaptic GABAARs and sleep slow waves.

22. Neutralizing IFN-γ autoantibodies are rare and pathogenic in HLA-DRB1*15:02 or 16:02 individuals.

23. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children.

24. Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.

25. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs.

26. Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency.

27. Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients.

28. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia.

29. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.

30. Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children.

31. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.

32. Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study.

33. Correction: Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency.

34. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α.

35. Autoantibodies against type I IFNs in patients with critical influenza pneumonia.

36. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.

37. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia.

38. Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency.

39. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.

40. A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes.

41. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.

42. Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child.

43. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths.

44. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1.

45. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.

46. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.

47. Autoantibodies against type I IFNs in patients with life-threatening COVID-19.

Catalog

Books, media, physical & digital resources